Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests

Journal of Clinical Virology

Volumn 38, Issue 3, 2007, Pages 204-209

  Tischer, Annedore ^a   Gassner, Markus ^b   Richard, Jean Luc ^c   Suter Riniker, Franziska ^d   Mankertz, Annette ^a   Heininger, Ulrich ^e  

^a ROBERT KOCH INSTITUTE   (Germany)

^b Grabs ^*  (Switzerland)

^c FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Enzyme immunoassay; Immunofluorescence test; Measles seroprevalence; MMR vaccination; Plaque neutralisation test

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

ADOLESCENT; ANALYTIC METHOD; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; MALE; MEASLES VACCINATION; MEASLES VIRUS; NORMAL HUMAN; PLAQUE NEUTRALIZATION TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SWITZERLAND;

ADOLESCENT; ANTIBODY SPECIFICITY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; NEUTRALIZATION TESTS; SEROEPIDEMIOLOGIC STUDIES; SWITZERLAND;

EID: 33847215882     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.12.017     Document Type: Article

References (29)

1. Albrecht P., Herrmann K., and Burns G.R. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Meth 3 (1981) 251-260
2. Andrews N., Pebody R.G., Berbers G., Blondeau C., Crovari P., Davidkin I., et al. The European Sero-Epidemiological Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol Infect 125 (2000) 127-143
3. Anonymus. Eliminating measles and rubella and preventing congenital rubella infection. WHO European Region strategic plan 2005-2010 (http://www.euro.who.int/Document/E87772.pdf).
4. Argüelles M.H., Orellana M.L., Castello A.A., Villegas G.A., Masini M., Belizan A.L., et al. Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine. J Clin Microbiol 44 (2006) 2733-2738
5. Baer G., Bonhoeffer J., Schaad U.B., and Heininger U. Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine 23 (2005) 2016-2020
6. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., et al. Measles antibody: reevaluation of protective titres. J Infect Dis 162 (1990) 1036-1042
7. Cohen B.J., Parry R.P., Doblas D., Samuel D., Warrener L., Andrews N., et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Meth 131 (2006) 209-212
8. Cohn M.L., Robinson E.D., Faerber M., Thomas D., Geyer S., Peters S., et al. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr Infect Dis J 13 (1994) 34-38
9. Davidkin I., and Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 16 (1998) 2052-2057
10. de Melker H., Pebody R.G., Edmunds W.J., Lévy-Bruhl D., Valle M., Rota M.C., et al. The seroepidemiology of measles in Western Europe. Epidemiol Infect 126 (2001) 249-259
11. Diaz-Ortega J.L., Forsey T., Clements C.J., and Milstein J. The relationship between dose and response of standard measles vaccines. Biologicals 22 (1994) 35-44
12. Dine M.S., Hutchins S.S., Thomas A., Williams I., Bellini W.J., and Redd S.C. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J Infect Dis 189 Suppl (2004) S123-S130
13. Feiterna-Sperling C., Brönnimann R., Tischer A., Stettler P., Durrer P., and Gaedicke G. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. Pediatr Infect Dis J 24 (2005) 1083-1088
14. Heininger U., and Zuberbühler M. Immunization rates and timely administration in pre-school and school-aged children. Eur J Pediatr 165 (2006) 124-129
15. Hesketh L., Charlett A., Farrington P., Miller E., Forsey T., and Morgan-Capner P. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. J Virol Meth 66 (1997) 51-59
16. Lee M.S., Nokes D.J., Hsu H.M., and Lu C.F. Protective titres of measles neutralising antibody. J Med Virol 62 (2000) 511-517
17. Matson D.O., Byington C., Canfield M., Albrecht P., and Feigin R.D. Investigation of a measles outbreak in a fully vaccinated school population including serum studies before and after revaccination. Pediatr Infect Dis J 12 (1993) 292-299
18. Matter L., Germann D., Bally F., and Schopfer K. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after introduction of MMR mass vaccination. Eur J Epidemiol 13 (1997) 61-63
19. Miller E., Hill A., Morgan-Capner P., Forsey T., and Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 13 (1995) 799-802
20. Mossong J., O'Callaghan C.J., and Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 19 (2000) 523-529
21. Paget J.W., Zimmermann H., and Vorkauf H. A national measles epidemic in Switzerland in 1997: consequences for elimination of measles by the year. Euro Surveill 5 2 (2000) 17-20
22. Pebody R.G., Gay N.J., Hesketh L.M., Vyse A., Morgan-Capner P., Brown D.W., et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 20 (2002) 1134-1140
23. Ratnam S., Gadag V., West R., Burris J., Oates E., Stead F., et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralisation test for detection of measles virus antibody. J Clin Microbiol 33 (1995) 811-815
24. Ratnam S., West R., Gadag V., Williams B., and Oates E. Immunity against measles in school-aged children: implications for measles revaccination strategies. Can J Public Health 87 (1996) 407-410
25. Richard J.-L., and Zimmermann H. Recent increase in measles in children and students in Switzerland. Eurosurv Wkl 7 23 (2003) 030605
26. Roost H.-P., and Zimmermann H. Repräsentative Erhebung zur Durchimpfung in der Schweiz 1998. Bull Swiss Federal Office Public Health 20 (1999) 356-361
27. Roost H.-P., Gassner M., Grize L., Wüthrich, Sennhauser F.H., Varonier H.S., et al. Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren. Pediatr Allergy Immunol 15 (2004) 401-407
28. Stohrer-Draxl P., Amstad H., Grize L., Gassner M., Takken-Sahli K., Bourquin C., et al. Masern, Mumps und Röteln: Durchimpfungsrate und Seroprävalenz bei 8.-Klässlern in acht verschiedenen Orten der Schweiz 1995/1996. Praxis 88 (1999) 1069-1077
29. Tischer A., and Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 18 (2000) 1382-1392